Understanding immune changes in arthritis caused by cancer treatments
Official title: Characterization of Altered Immunity in Patients with Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy
Funded at Yale University · NIH-10892882 · Data updated 2026-11-12
This study is looking at how a cancer treatment called immune checkpoint inhibitors might cause joint pain and inflammation in some patients, and it aims to understand how the immune system, especially certain immune cells, is involved in this process to help improve care for those affected.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $173,556 |
| NIH project number | 5K08AR079587-04 |
| Project ID | NIH-10892882 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients receiving immune checkpoint inhibitors for advanced cancer who are experiencing symptoms of inflammatory arthritis.
✕Less likely to help
Patients who are not undergoing immune checkpoint inhibitor therapy or do not have arthritis as a side effect may not benefit from this research.
What this research studies
This research investigates how immune checkpoint inhibitor therapy, a treatment for advanced cancer, can lead to inflammatory arthritis in patients. The principal investigator, Dr. Sang Kim, aims to explore the immune system's response, particularly focusing on T cells and their role in this condition. By utilizing advanced genomic technologies, the study will analyze the biological markers and immune signatures in patients experiencing arthritis as a side effect of their cancer therapy. This research could provide insights into managing and preventing these adverse effects for better patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for managing arthritis in patients undergoing cancer treatment.
How similar studies have gone: Other research has shown promising results in understanding immune-related adverse events in cancer therapies, indicating that this approach has potential for success.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Kim, Sang Taek — Yale University
- Study coordinator: Kim, Sang Taek
Related research
Other NIH-funded projects on the same topics.
-
ctDNA biomarker to guide safety of cancer immunotherapy in inflammatory arthritis
A patient-facing biomarker study using a blood test to detect tumor DNA in people with cancer who develop inflammatory arthritis from immunotherapy, to help doctors pick safer treatment choices.
-
Understanding immune-triggered inflammatory arthritis from cancer immunotherapy
A clinical study looks at why inflammatory arthritis caused by cancer immunotherapy affects people differently and how to best treat it.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Antenatal DMARD Use and Mother-Child Health in Women with Chronic Inflammatory Arthritis
This project aims to understand how continuing pregnancy-safe arthritis medicines during pregnancy affects health outcomes for mothers with chronic inflammatory arthritis and their babies.
-
Gut barrier and antibiotics: how gut health affects inflammatory arthritis
Antibiotic use may increase the risk of inflammatory arthritis by changing the gut, and this project looks at how those gut changes influence joint inflammation in people with arthritis.
-
Setbp1’s role in how joint cells behave during inflammatory arthritis
This project looks at how a protein called SETBP1 affects delicate joint cells (FLS) that drive inflammation in arthritis, with potential implications for better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.